Thermo Fisher Scientific Launches Integrated Drug Development Services

Pharmaceutical and biotech companies are facing increasing challenges in drug development, including rising costs and complex regulatory environments. In response, Thermo Fisher Scientific has introduced a new suite of services called **Accelerator Drug Development**. This initiative integrates contract development and manufacturing organization (CDMO) and contract research organization (CRO) capabilities to streamline the process from early-stage research to commercialisation.

In a recent discussion with **Nicole Raleigh**, web editor at pharmaphorum, **Alberto Fernández**, Head of Clinical Development Strategy & Innovation at Thermo Fisher Scientific, detailed the motivations behind this new solution. He explained how it is designed to support both small and mid-sized biotech firms, as well as larger pharmaceutical companies, across various drug modalities and therapeutic areas.

Accelerator Drug Development aims to alleviate the burdens associated with traditional models that often require multiple vendors. By offering an integrated approach, Thermo Fisher seeks to simplify the drug development journey, ultimately enhancing efficiency and effectiveness.

Alberto Fernández brings over 32 years of experience in the life sciences and pharmaceutical research and development sector. His career began as a Clinical Research Associate (CRA) in Spain, advancing through significant roles including executive leadership positions at **GSK** and **AstraZeneca**. In his current role, Fernández collaborates across digital and corporate functions to implement innovative strategies within clinical research.

His educational background includes a Bachelor of Science (BSc) and a Master of Science (MSc) in Biology from **Universidad Complutense de Madrid**. He also holds a Global Executive MBA from **IESE Business School** and has completed advanced leadership programs at both IESE and **Harvard Business School**.

Thermo Fisher Scientific, with an annual revenue exceeding **$40 billion**, is recognized as a leader in scientific services. The company’s mission is to enable customers to create a healthier, cleaner, and safer world. Its offerings range from life sciences research and analytics to diagnostics and the development of transformative therapies.

As the pharmaceutical landscape continues to evolve, Thermo Fisher’s Accelerator Drug Development solution aims to address the unique needs of organizations navigating these complexities. For further details on this innovative service, visit **www.thermofisher.com**.